Option Care Health, Inc.
OPCH
Rangering i aksjer
#3626
Option Care Health, Inc. delivers infusion services to patients in their homes... Option Care Health, Inc. delivers infusion services to patients in their homes and other non-hospital settings throughout the United States. The company offers a broad spectrum of specialized infusion treatments, including therapies for various infections, management of heart failure, and comprehensive nutritional support (both intravenous and tube feeding) for individuals with acute or chronic conditions such as stroke, cancer, and digestive illnesses. They also provide immunoglobulin infusions for immune system deficiencies and treatments targeting chronic inflammatory disorders like Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Furthermore, Option Care Health assists in managing the progression of neurological conditions such as amyotrophic lateral sclerosis (ALS) and Duchenne muscular dystrophy. They also administer infusion therapies for bleeding disorders and provide crucial support for women experiencing high-risk pregnancies. Other specialized infusion services encompass pain relief, chemotherapy, and respiratory care. Complementing these medical offerings, the company provides professional nursing services. Option Care Health, Inc. maintains its primary corporate office in Bannockburn, Illinois.
Aksjekurs
$31.32
Markedsverdi
$4.69B
Endring (1 dag)
0.34%
Endring (1 år)
10.35%
Land
US
Handel Option Care Health, Inc. (OPCH)
Kategori
Healthcare
P/E-forhold for Option Care Health, Inc. (OPCH)
P/E-forhold per October 2026 TTM: 23.40
Ifølge Option Care Health, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 23.40. Ved slutten av 2023 hadde selskapet en P/E på 22.58.
P/E-forholdshistorikk for Option Care Health, Inc. fra 2000 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 23.40 | 24.53% |
| 2024 | 18.79 | -16.76% |
| 2023 | 22.58 | -37.63% |
| 2022 | 36.20 | -1.00% |
| 2021 | 36.56 | -110.43% |
| 2020 | -350.47 | 1,041.12% |
| 2019 | -30.71 | 247.59% |
| 2018 | -8.84 | 53.56% |
| 2017 | -5.75 | 144.98% |
| 2016 | -2.35 | 485.44% |
| 2015 | -0.40 | -87.64% |
| 2014 | -3.25 | -52.68% |
| 2013 | -6.86 | -173.27% |
| 2012 | 9.36 | -75.24% |
| 2011 | 37.80 | -1,092.14% |
| 2010 | -3.81 | -163.25% |
| 2009 | 6.02 | -622.95% |
| 2008 | -1.15 | -101.31% |
| 2007 | 87.73 | -2,702.59% |
| 2006 | -3.37 | -68.76% |
| 2005 | -10.79 | -153.64% |
| 2004 | 20.12 | 17.87% |
| 2003 | 17.07 | 143.10% |
| 2002 | 7.02 | -73.58% |
| 2001 | 26.57 | -373.26% |
| 2000 | -9.72 | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| 15.70 | -32.89% |
US
|
|
| - | - |
DE
|
|
| 10.40 | -55.56% |
US
|
|
| 32.07 | 37.06% |
SA
|
|
| 20.00 | -14.52% |
BR
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.